[Buserelin therapy in postmenopausal patients with advanced breast carcinoma].

Twenty-seven postmenopausal women with advanced breast cancer were treated with the potent LHRH-agonist buserelin. The drug was given s.c. three times daily at a daily dosage of 3 mg the first week and subsequently of 2 mg daily. Although pituitary gonadotropins were suppressed in all cases, no response was observed in 26 evaluable patients. This study does not confirm earlier findings suggesting a role for LHRH-agonists in the treatment of postmenopausal patients with breast cancer.